Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. - Wikidata - awgldk - TriplyDB

Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

http://www.wikidata.org/entity/Q44824434

about

Physiologically based pharmacokinetic modeling of persistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies Aging and the environment: a research framework Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling.Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse.Studying permethrin exposure in flight attendants using a physiologically based pharmacokinetic model Apparent half-lives of dioxins, furans, and polychlorinated biphenyls as a function of age, body fat, smoking status, and breast-feeding Levels of persistent organic pollutant and their predictors among young adults.Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.Distributions of Autocorrelated First-Order Kinetic Outcomes: Illness Severity.Modeling the Human Kinetic Adjustment Factor for Inhaled Volatile Organic Chemicals: Whole Population Approach versus Distinct Subpopulation Approach Review and analysis of inhalation dosimetry methods for application to children's risk assessment.Computational pharmacokinetics during developmental windows of susceptibility.Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation.The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Whole-body physiologically based pharmacokinetic models.Approaches for applications of physiologically based pharmacokinetic models in risk assessment.Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate.An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry.Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants.Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.Physiologically based pharmacokinetic model for quinocetone in pigs and extrapolation to mequindox.Modeling Pharmacokinetics.Have physiologically-based pharmacokinetic models delivered?Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences.Dosimetric adjustments for interspecies extrapolation of inhaled poorly soluble particles (PSP).High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication.Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.Clinical relevance of predictive physiologically based pharmacokinetic methods.Sex differences in urinary levels of several biological indicators of exposure: a simulation study using a compartmental-based toxicokinetic model.Age-dependent partition coefficients for a mixture of volatile organic solvents in Sprague-Dawley rats and humans.Modern methodologies and tools for human hazard assessment of chemicals A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.Organ growth functions in maturing male Sprague-Dawley rats.Carbaryl and 1-naphthol tissue levels and related cholinesterase inhibition in male Brown Norway rats from preweaning to senescence.Linking fate model in freshwater and PBPK model to assess human internal dosimetry of B(a)P associated with drinking water.Options for incorporating children's inhaled dose into human health risk assessment.Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage.Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.

P2860

Q24644907-F24B61F3-64E8-4BA5-88FC-E1B9F37FB32D Q24815677-26273E88-9E86-4C21-98E7-858C61A0F3A0 Q28389663-D1A489EF-3C9A-4A9D-AB6E-A38C50270CB8 Q31077784-F2596467-A3E2-4F3A-AB0B-74A2BF330E60 Q33585007-4713D7B7-10F8-4AE3-A80C-A72FDC50EB44 Q33777528-35FD94E5-E01D-486E-88F4-16B66310DB46 Q34972720-685D0D8E-9850-4015-B4C9-DAE133612396 Q34985280-308FAB24-6F47-40CB-B1A4-4A067C81931C Q35054518-3AF2696F-BC42-4F7F-8BD4-2C82F1846AE7 Q35659714-5A32DB02-04D6-4858-B3E8-4472EC37D2D1 Q35864881-3A1136EC-76F2-4DF7-ABDF-D83495E28F20 Q36131290-9FF200EE-FE65-4475-A228-B6DCE0E5B8CF Q36195215-B5A8EC5B-4ECA-41A2-B7AC-93BB70B3978E Q36657666-7DA8042E-B35E-47C3-B01F-4C1B5BD2427F Q36683248-2067A8A1-1E96-47AF-B6D6-DF8B73D275C6 Q36788418-F31B8FC0-3671-4C91-B9AF-6245F06D28D4 Q37201545-85D70B32-3848-405E-BF41-08D2CF90C3A3 Q37916566-AA7609A2-8AE8-455C-8AEC-96AC3D0DAA68 Q38041230-F0838740-3A61-47A5-A699-F02BA65B64DC Q38137867-9918BB34-8B02-4AB1-BB56-34C1C974653F Q38357598-4DEA19A2-3E06-4CE4-A367-D8745C74C26D Q38691542-B88B7D0A-C9F6-4176-96FF-401C06AFB898 Q39077905-58F72174-78B9-403B-9CB1-ADACB02C7D7F Q39677925-D7D84AFC-42DC-47FC-AE7A-10FD439D64BA Q39728369-9FFCC619-50D7-440F-9272-517ECD3C6280 Q40148266-ACD1A9DB-3D37-428E-ABA4-B71F07E5CCDB Q40405326-98B4772B-9ADA-453C-ADFE-4E00CF31D0FE Q41103874-8376DAA7-9410-4810-9023-72082074B989 Q42410356-B111B051-D031-47B9-A1CE-FE9AA2760FDC Q43998919-702D6D1C-CEC8-4EB6-AA9D-A3E4B9FE760D Q44368114-72A1DFDF-EAD0-4D4D-850A-E1EF13BAE2FC Q46988643-E49E8E04-68D2-478F-902E-7709F0C6ED07 Q47154406-CC4B1B1B-EA4B-447A-B348-868DA89E508F Q47254105-5E95793B-EFF2-445A-ADC1-D0730B77DDE6 Q48190885-D1450FE2-111B-4E69-AAB7-CCEFE26B625B Q48844032-654074B6-4F45-40B1-924B-3062FB35A6AA Q51161726-56375D40-E949-4FA4-809E-BED16D8C90AF Q51690519-5932BD1E-D164-4AD5-A1C3-620EAD733F92 Q51988108-82108710-03FA-4D6C-A553-E97F5B6182B9 Q53236816-DCA61858-778F-4626-B528-75B1DFB577CB

P2860

Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

http://www.wikidata.org/entity/Q44824434

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Evaluation of the potential im ...... fferences on tissue dosimetry.

@en

Evaluation of the potential im ...... fferences on tissue dosimetry.

@nl

type

label

Evaluation of the potential im ...... fferences on tissue dosimetry.

@en

Evaluation of the potential im ...... fferences on tissue dosimetry.

@nl

prefLabel

Evaluation of the potential im ...... fferences on tissue dosimetry.

@en

Evaluation of the potential im ...... fferences on tissue dosimetry.

@nl

P1433

Q44824434-9B9BD652-5FCE-4B2D-8B66-53C0CE4474B3

P1476

Q44824434-8D9BBC8F-DCC4-45B1-BB66-603F8010C490

P2093

Q44824434-0E66ADFF-2B25-4249-8FD3-4195745072A5

Q44824434-18D7DC2C-FB85-4DD0-B829-FF7A7F688275

Q44824434-5E503B82-4361-4355-AB83-416FA87985C0

Q44824434-B63EEEBA-FF41-4A86-B2E0-D9A32C16B858

P2860

Q44824434-0C4AD144-0FAE-41AC-AD03-2D81D9273655

Q44824434-1224AA72-106A-4E1E-A1A9-9B8DBDEBE572

Q44824434-150B6DF3-188B-44A8-B907-19981AD04533

Q44824434-170FE856-CA15-4429-82D9-0BB0202BD2F1

Q44824434-173FB294-7E53-4DE7-9074-AE561D59D61A

Q44824434-2909E08B-5012-4DD3-968B-DB40FEBBEF82

Q44824434-357854FE-6A44-4191-850D-2EF6AD908D45

Q44824434-469A185B-1411-4535-B998-81249B0B484F

Q44824434-5A30BB3A-CDBE-4EFE-8C16-9FD1970338CC

Q44824434-71C67951-AA74-427A-B571-522ECF2F54BA

P304

Q44824434-DA671383-FAD6-49E3-812D-5E88C083FC94

P31

Q44824434-7359B8CC-6B6A-4960-B37A-F6C8E4C666C1

P356

Q44824434-04D44D42-27B1-4648-AB0D-80F7FDEB179E

P433

Q44824434-F58856CD-4CF7-43C6-89F8-EC7C3A310996

P478

Q44824434-A5761592-13C1-4C65-AB5C-8FB398D7678C

P50

Q44824434-CF5487B3-D418-45F0-A081-A92DF9EFF2C7

P577

Q44824434-71148319-ACAD-4666-8B87-A94B7B50DBDF

P5875

Q44824434-BE343444-9A81-4FF6-A314-F862554DAF57

P698

Q44824434-ACA04CA4-CFB4-4F40-86F3-8D5750E3FE54

P356

P1433

Toxicological Sciences

P1476

Evaluation of the potential im ...... fferences on tissue dosimetry.

@en

P2093

Harvey J Clewell

http://www.w3.org/2001/XMLSchema#string

P Robinan Gentry

http://www.w3.org/2001/XMLSchema#string

Ramesh Sarangapani

http://www.w3.org/2001/XMLSchema#string

Tammie R Covington

http://www.w3.org/2001/XMLSchema#string

P2860

Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects

Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model.

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period.

Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration.

Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

Pharmacokinetics in the elderly.

Pharmacokinetics in the infant.

Assessing cancer risks from short-term exposures in children.

Pharmacokinetics in the newborn.

P304

381-393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/TOXSCI/KFH109

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Justin Teeguarden

P577

2004-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8644100

http://www.w3.org/2001/XMLSchema#string

P698

15056818

http://www.w3.org/2001/XMLSchema#string